Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25136133.
- Also identified by DOI 10.1073/pnas.1400478111 and PMC identifier 4151741.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Innate immunity confers an immediate nonspecific mechanism of microbial recognition through germ line-encoded pattern recognition receptors (PRRs). Of these, Toll-like receptors (TLRs) and nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) have shaped our current understanding of innate regulation of adaptive immunity. It is now recognized that PRRs are paramount in instructing an appropriate adaptive immune response. Their ligands have been the focus of adjuvant research with the goal of generating modern vaccine combinations tailored to specific pathogens. In this review we will highlight the recent findings in the field of adjuvant research with a particular focus on the potential of TLR and NLR ligands as adjuvants and their influence on adaptive immune responses.
Medical subject headings
- Adjuvants, Immunologic
- Nod Signaling Adaptor Proteins
- Toll-Like Receptors
- Vaccines